Mark Talamonti to Camptothecin
This is a "connection" page, showing publications Mark Talamonti has written about Camptothecin.
Connection Strength
0.095
-
Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study. J Surg Oncol. 2018 Mar; 117(3):354-362.
Score: 0.034
-
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101. JAMA Surg. 2016 08 17; 151(8):e161137.
Score: 0.032
-
Pancreatic cancer and FOLFIRINOX: a new era and new questions. Cancer Med. 2015 Jun; 4(6):853-63.
Score: 0.029